The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron
- Acceleron Pharma Inc (NASDAQ: XLRN) shares have plunged 23 percent since December 21.
- Credit Suisse’s Kennen MacKay initiated coverage of the company with an Outperform rating and a price target of $50.
- The Street is less bullish about luspatercept due to competition from gene therapy.
Analyst Kennen MacKay believes that luspatercept has the potential to become a blockbuster drug, which could be a long-term treatment for beta-thal and MDS patients. He added, however, that the Street seems to be discounting the drug’s value due to potential competition from gene therapy in beta-thal.
Related Link: Credit Suisse Bullish On Most Big Pharma Names
Acceleron’s beta-thal phase 3 strategy “has been refined through lessons learned” from the phase 2 experience. This, together with recent gene therapy setbacks, supports peak sales estimate of $1 billion, MacKay commented. He added that there could be an additional $1 billion for RS+ MDS in which luspatercept exhibited the highest responses in phase 2.
In the report Credit Suisse noted, “Dalantercept + axitinib showed promising early ORR, PFS, and OS data in refractory RCC, nearly doubling PFS over SoC. We see potential for ~$900M in peak RCC sales…We also see this program as overlooked given its early-stage development, but we note the potential for rapid approval given the severity and lack of treatment options for refractory RCC patients.”
After closing up more than 5 percent on Wednesday, shares were down about 4.8 percent in Thursday's pre-market session.
Latest Ratings for XLRN
|Sep 2016||Citigroup||Initiates Coverage on||Neutral|
|Aug 2016||BTIG Research||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.